Laura J. Esserman
Breast surgeon who built the I-SPY platform, the adaptive trial that tests new drugs before surgery.
Laura Esserman is a breast surgeon and trial innovator. Esserman leads I-SPY 2, the adaptive neoadjuvant platform trial, and the WISDOM study of risk-based breast screening. A prominent voice on overdiagnosis and de-escalation.
| Title | Journal | Year |
|---|---|---|
| Adaptive Randomization of Neratinib in Early Breast Cancer | New England Journal of Medicine | 2016 |
| Rethinking screening for breast cancer and prostate cancer | JAMA | 2009 |
Pages like this
not linked directly; found by shared links- TechnologyMirai (MIT breast cancer risk from mammograms)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaOne-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaSet each woman's mammogram interval from her last mammogram, using AI risk
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CollectionSusan G. Komen
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- Key paperMASAI: AI-supported mammography screening finds more cancers with half the radiologist workload
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- PersonTakayuki Ueno
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionTianjin Medical University Cancer Institute and Hospital
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)
Shares Residual cancer burden (RCB), Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).